Skip to content

Early screening of diabetes mellitus complicated with cognitive impairment

Early screening of diabetes mellitus complicated with cognitive impairment

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051164
Enrollment
Unknown
Registered
2021-09-15
Start date
2021-10-15
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic encephalopathy (DE)

Interventions

Diabetes mellitus without cognitive impairment group:None
Diabetes mellitus with cognitive impairment group:None
Control group:None

Sponsors

The First Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Subjects aged between 40 and 80 years; 2. All subjects with type 2 diabetes met the 1999 WHO diagnostic criteria for diabetes, and had a stable hypoglycemic regimen within the past 3 months; 3. Have not used antibiotics, lactulose, viable microbial preparations, etc. within 2 months before entering the study.

Exclusion criteria

Exclusion criteria: 1. Diabetic ketoacidosis, hyperglycemia and hyperosmolar state or severe and repeated hypoglycemia events in the past 3 months, thyroid, parathyroid and other endocrine-related diseases; 2. Patients with severe anemia, severe heart disease, liver and kidney dysfunction or other systemic history of systemic diseases; 3. Gastrointestinal diseases; 4. Acute infection; 5. Patients with malignant tumors and autoimmune diseases; 6. History of severe neuropsychological, mental illness, alcoholism or abuse of psychotropic substances; 7. There are serious neurological diseases (cerebrovascular disease, tumor, stroke, Parkinson's, brain trauma, etc.); 8. Those with visual and hearing impairments.

Design outcomes

Primary

MeasureTime frame
Fasting blood glucose;Fasting insulin;Glycosylated hemoglobin;8-Hydroxydeoxyguanylate;IL-1ß;IL-6;Amyloid A;Phosphorylated Tau;End products of glycation;microRNA-34c;

Countries

China

Contacts

Public ContactXu Shunjiang

The First Hospital of Hebei Medical University

sjxu66@sina.com+86 18630112559

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026